<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics

    MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.

    Biodesix Announces New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy

    Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.


    Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery

    Biodesix highlighted their development and commercialization of companion diagnostics for directing the treatment of non-small cell lung cancer at the 2019 Clinical Biomarkers & World CDx Conference.

    Biodesix to Acquire Oncimmune in the United States

    Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.

    Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR

    Biodesix will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy

    Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team

    Biodesix appointed Robert W. Georgantas III, Ph.D., as the company’s Senior Vice President (SVP) of Research and Translational Science.

    Biodesix Reaches Agreement to Deliver Next-Generation Sequencing Assay for Blood-Based Companion Diagnostic Solutions in Cancer

    Biodesix has entered into an agreement with Thermo Fisher Scientific.

    Biodesix Names Dr. James Jett Chief Medical Officer

    Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.

    Biodesix VeriStrat Data Demonstrate Independent Prediction of Immunotherapy Outcomes for NSCLC Patients

    Biodesix presented new data showing that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer treated with immune checkpoint inhibitors

    Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers

    Biodesix announced that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.

    Biodesix Adds Dr. Charles Watts to Board of Directors

    Biodesix announces the appointment of Charles Watts, M.D. to the company’s board of directors.


    Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device

    Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD).

    Biodesix Named Company of the Year by Colorado BioScience Association

    Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association. The company was honored at the 16th Annual CBSA Awards Dinner.

    AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study

    AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML.

    Biodesix Completes Acquisition of Oncimmune Assets in the United States

    Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.


    Biodesix Appoints Scott Hutton as Chief Executive Officer

    Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.


    Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

    Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.